Let's talk: editor@tmv.in
NATCO Pharma Receives Seven USFDA Observations After Hyderabad Plant Inspection

NATCO Pharma Receives Seven USFDA Observations After Hyderabad Plant Inspection

Saikiran Y
November 22, 2026

NATCO Pharma Limited has received seven observations from the US Food and Drug Administration (USFDA) following an inspection of its formulations manufacturing facility at Kothur in Hyderabad, Telangana, between November 12 and 20, 2026. The company said it considers the observations procedural in nature and is confident of addressing them comprehensively within the stipulated timelines.

In a regulatory filing on Saturday, the Hyderabad-headquartered pharmaceutical company confirmed that the US regulator issued seven observations in Form FDA 483 upon completion of the inspection. However, it did not disclose the specific deficiencies identified or the corrective measures proposed to address them.

The USFDA conducts pharmaceutical inspections to verify compliance with Current Good Manufacturing Practices (cGMP), which establish standards for manufacturing processes, quality control, laboratory testing, documentation and facility maintenance to ensure medicines meet prescribed standards of identity, strength, quality and purity.

The regulator follows a six-system inspection approach covering the Quality System, Facilities and Equipment, Materials, Production, Packaging and Labelling, and Laboratory Controls. A full inspection generally covers at least four systems, while an abbreviated inspection covers at least two, with the Quality System included in both. The exact areas examined at NATCO's Kothur facility have not been disclosed.

Standard Operating Procedures (SOPs) are central to these requirements. Pharmaceutical manufacturers must maintain approved written procedures covering equipment cleaning, manufacturing operations, material handling, sampling, laboratory testing, calibration and packaging. Employees must follow these procedures, undergo appropriate training and maintain records of activities. Deviations must be documented, investigated and justified. Under 21 CFR Part 211, production and process-control procedures must be reviewed, approved and followed consistently.

A Form 483 communicates conditions that investigators believe may constitute regulatory violations. However, it is not a final determination of non-compliance or an automatic enforcement action. Companies are generally encouraged to submit written responses within 15 business days, detailing corrective and preventive actions (CAPA).

The USFDA subsequently evaluates inspection findings and company responses before assigning a classification: No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI).

NATCO Pharma operates across more than 50 international markets and has manufacturing facilities approved by regulatory authorities including the USFDA, Brazil's ANVISA, Health Canada and the World Health Organization. Its business focuses on generic medicines, specialty pharmaceuticals, oncology treatments and active pharmaceutical ingredients (APIs).

NATCO Pharma Receives Seven USFDA Observations After Hyderabad Plant Inspection - The Morning Voice